Background Few treatments with a distinct mechanism of action are available for patients with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed the efficacy and safety of treatment with docetaxel plus either ramucirumab-a human IgG1 VEGFR-2 antagonist-or placebo in this patient population.
Introduction
Platinum-based combination chemotherapy is standard front-line treatment for patients with advanced or metastatic urothelial carcinoma, with median overall survival of 11-15 months depending on the type of platinum chemotherapy that can be administered and baseline clinical prognostic factors. [1] [2] [3] [4] Despite objective responses of 40-70%, the duration of response is limited and most patients become refractory. Prognosis in refractory patients remains poor, with median overall survival with single-agent cytotoxic therapy of approximately 7 months.
Immune-checkpoint inhibitors targeting the pro grammed cell death 1 protein (PD-1) and its ligand (PD-L1) have shown clinical activity in patients with platinum-refractory urothelial carcinoma. Accelerated or full approval has been granted in the USA to five agents of this class based on objective responses of 15-21%. [6] [7] [8] [9] [10] However, many patients treated with immune-checkpoint inhibitors have progressive disease as their best response, highlighting that other targets and treatments are needed. [6] [7] [8] [9] [10] [11] Vascular endothelial growth factor receptors (VEGFRs) 1 and 2 and their ligands are important mediators of tumour angiogenesis and contribute to the pathogenesis and progression of urothelial carcinoma. [11] [12] [13] [14] [15] [16] [17] [18] [19] Ramucirumab is an IgG1 monoclonal antibody that binds to the extracellular domain of VEGFR-2, competing with VEGFA, VEGFC, and VEGFD. 20 There is strong rationale for testing the combination of ramucirumab and docetaxel in platinum-refractory urothelial carcinoma because preclinical data suggest synergy, and docetaxel is used widely as a single agent across the globe in this setting. [21] [22] [23] [24] In a randomised phase 2 study in patients with platinum-refractory advanced or metastatic urothelial carcinoma, ramucirumab plus docetaxel significantly improved median progression-free survival compared with docetaxel alone (5·4 months vs 2·8 months; hazard ratio [HR] 0·389, 95% CI 0·235-0·643; p=0·0002). 13 To confirm these results, we did a randomised phase 3 trial (RANGE) in a similar patient population. Here, we report the primary analysis of investigator-assessed progression-free survival. Data for overall survival are immature at the time of this publication, prohibiting formal testing of objective response; overall survival outcomes will be reported once mature.
Methods

Study design and participants
We did a double-blind, multicentre, randomised, phase 3 trial at 124 investigative sites in 23 countries (appendix pp [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Full inclusion and exclusion criteria are provided in the study protocol (appendix pp . Briefly, patients aged 18 years or older were eligible for enrolment if they had: histologically or cytologically confirmed carcinoma of pure or predominant transi tional cell histology; locally advanced, unresectable, or metastatic disease extent; primary tumour originating from the bladder, urethra, ureter, or renal pelvis; and progression 14 months or less after platinum-containing chemotherapy (2 additional months were allowed for screening and patient identification over the standard 12 months). 25 We permitted previous treatment with one immune-checkpoint inhibitor for patients who relapsed 24 months or less from the end of a platinum-containing regimen, allowing an additional 10 months for patients who received both platinum and immune-checkpoint inhibitors. Furthermore, patients had
Research in context
Evidence before this study We searched PubMed, abstracts of major oncology congresses (eg, American Society of Clinical Oncology [ASCO] and ASCO Genitourinary Cancer Symposium, and European Society for Medical Oncology), and clinical trial websites (including ClinicalTrials.gov), with no date restrictions, for preclinical reports and clinical trials (published in English) assessing chemotherapy, antiangiogenic therapies, and a combination of these methods in urothelial carcinoma. Multiple single-agent cytotoxic therapies (eg, docetaxel) showed modest activity in this patient population. Findings of a randomised phase 2 study (NCT01282463) in patients with platinum-refractory advanced or metastatic urothelial carcinoma showed that ramucirumab plus docetaxel significantly improved median progression-free survival versus docetaxel alone. Ramucirumab is an IgG1 monoclonal antibody that binds to the extracellular domain of vascular endothelial growth factor receptor 2 (VEGFR-2), which is an important mediator of tumour angiogenesis. Thus, after review of the scientific literature and discussions with clinicians, researchers, and regulatory agencies, we undertook the phase 3 RANGE trial of ramucirumab plus docetaxel versus placebo plus docetaxel in patients with platinum-refractory advanced or metastatic urothelial carcinoma. As our study protocol was being developed, emerging evidence suggested immune-checkpoint inhibitors targeting the programmed cell death 1 protein (PD-1) and its ligand (PD-L1) had clinical activity in a subset of patients with platinum-refractory urothelial carcinoma. Therefore, we included in our study patients who received one previous immune-checkpoint inhibitor.
Added value of this study
Compared with placebo plus docetaxel, ramucirumab plus docetaxel improved progression-free survival and objective responses without additive toxic effects or compromising quality of life in patients with platinum-refractory advanced or metastatic urothelial carcinoma. The responses reported in our phase 3 trial are in line with those noted with immune-checkpoint inhibitors in other studies.
Implications of all the available evidence
Taken together with results from the previous phase 2 study in a similar patient population, our phase 3 data show that inhibition of VEGFR-2-mediated signalling yields meaningful clinical activity in patients with platinum-refractory advanced or metastatic urothelial carcinoma. To the best of our knowledge, ramucirumab is the only antiangiogenic agent to show such activity in this patient population. Furthermore, RANGE is the first phase 3 trial as far as we are aware to show a progression-free survival advantage over chemotherapy alone in platinum-refractory advanced or metastatic urothelial carcinoma. These results confirm the benefit of adding an anti-VEGFR-2 antibody to standard chemotherapy in this setting and represent progress in the treatment of urothelial carcinoma.
to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Key exclusion criteria included more than one previous systemic chemotherapy in the relapsed or metastatic setting (previous systemic therapy in the perioperative setting was not judged a previous line); previous systemic taxane; untreated brain metastases; haemoglobin lower than 9 g/dL; and an arterial or venous thromboembolic event 6 months or less before randomisation.
The trial adhered to the Declaration of Helsinki, the International Conference on Harmonisation Guidelines for Good Clinical Practice, and applicable local regulations. The protocol was approved by the ethics committees of all participating centres, and patients provided written informed consent before study entry. An independent data monitoring committee assessed unblinded safety data throughout the study.
Randomisation and masking
Patients were randomly allocated treatment using an interactive web response system, with a computergenerated random sequence. Randomisation was strat ified by: geographic region (North America, east Asia, and Europe and the rest of the world); ECOG performance status at baseline (0 or 1); and visceral disease (yes or no), when visceral disease involved the liver, lung, bone, or a combination. Patients, study staff, and the study funder were unaware of treatment assignment. For masking, allocated treatments were volume equiv alent and in identical-appearing containers.
Procedures
We administered intravenous docetaxel 75 mg/m² (60 mg/m² in Korea, Taiwan, and Japan) to all patients then either intravenous ramucirumab 10 mg/kg or placebo 10 mg/kg volume equivalent, as per the random assignment, on day 1 of a 21-day cycle. Treatments were continued until disease progression or unacceptable toxic effects. Docetaxel was restricted to six cycles; up to four additional cycles could be given after funder approval. There was no planned crossover on disease progression. We allowed dose modifications of any administered study drug, according to protocol-defined criteria. We permitted use of granulocyte-colony stimulating factors based on American Society of Clinical Oncology guidelines. 26 We assessed tumour response radiographically according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 at baseline, every 6 weeks after randomisation for the first year, and then every 12 weeks thereafter. Radiological assessments were analysed by investigators at local sites and reviewed by an independent blinded assessment group (BIOCLINICA, Princeton, NJ, USA). After discontinuation, we followed up patients for survival every 3 months. The appendix (pp 17-144) provides details of the timing of other assessments. We graded adverse events using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. We assessed patient-reported outcomes using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) version 3.0 and the EQ-5D-5L questionnaire, which measure quality of life and health status, respectively. QLQ-C30 is scored on a scale from 0 to 100, according to the EORTC scoring manual, and the EQ-5D-5L index was calculated using the English value set. 27 For QLQ-C30, we defined time to sustained deterioration as time from randomisation to the first 10 point or greater worsening with no subsequent on-therapy assessment that returned to or improved from baseline score.
Outcomes
The primary endpoint was progression-free survival as assessed by the investigator, defined as the time from randomisation until first radiographic documentation of objective progression, or as death from any cause. Secondary endpoints included: overall survival, defined as the time from randomisation to death from any cause; objective response, defined as the proportion of patients with a best overall response of complete or partial response; disease control, defined as the proportion of patients with a best overall response of complete response, partial response, or stable disease; duration of response, defined as the first date of complete or partial response until the first date of objective progression, or death; safety; patient-reported outcomes; pharmacokinetics of ramucirumab; and immuno genicity of ramucirumab. The appendix (pp 17-144) provides the full assessment schedule. Here, we report the primary analysis of investigator-assessed progression-free survival and data for all secondary analyses with the exception of overall survival, for which data were immature at the time of data cutoff.
Statistical analysis
We planned to enrol 524 patients in a 1:1 randomisation, with the primary analysis to be done when at least 331 progression-free survival events were reported. We assumed 15% patient dropout and estimated that roughly 437 patients would be needed to reach 331 progression-free survival events. The number of events provided 90% power to detect progression-free survival superiority of ramucirumab plus docetaxel versus placebo plus docetaxel, assuming an HR of 0·70 with a two-sided α of 0·05. The sample size was also powered to show an overall survival superiority between the two treatment groups, with an assumed HR of 0·75 for ramucirumab plus docetaxel versus placebo plus docetaxel with at least 382 events, power of 80%, and a two-sided type I error of 0·05.
We assessed progression-free survival and response in the first 437 patients of the intention-to-treat (ITT) 28, 29 included liver metastases, haemoglobin <10 g/dL, ECOG performance status score >0, and time since completion or discontinuation of previous treatment of <3 months. †A summary of previous anticancer treatments is included in the appendix (p 13). ‡Among the first 437 randomised patients, one patient allocated ramucirumab received nivolumab or placebo in a previous clinical trial, but we do not know whether that patient actually received nivolumab, so they are not included in this total. population, which included all randomised patients. We used the full ITT population to assess patient-reported outcomes. We estimated progressionfree survival using the Kaplan-Meier method, and we compared outcomes between treatment groups using a stratified log-rank test. We estimated HRs and associated 95% CIs using a stratified Cox proportional hazard model. We summarised patient-reported outcome data descrip tively. We compared time to sustained deterior ation using a non-stratified log-rank test. We assessed safety in all patients who received at least one dose of study medication (safety population). We implemented a gatekeeping design to assess progression-free survival, overall survival, and objective response in a fixed sequential manner. This study is registered with ClinicalTrials.gov, number NCT02426125.
Role of the funding source
The funder designed the trial, in collaboration with the scientific council (including DPP, RdW, KNC, CNS, HN, and TP), and was responsible for data management and statistical analysis. The funder interpreted data in collaboration with all authors and supported development of the report by providing medical writing and editorial assistance. The corresponding author had full access to all data in the study and all authors had final responsibility for the decision to submit for publication.
Results
Between July, 2015, and April, 2017, 727 patients were screened for study eligibility of whom 197 were excluded mainly for not meeting inclusion criteria (figure 1); 530 patients were randomly allocated either ramucirumab plus docetaxel (n=263) or placebo plus docetaxel (n=267) and comprised the ITT population. Baseline charac teristics were balanced between treatment groups in the ITT population (table 1; appendix p 13) and in the first 437 randomised patients (appendix pp 11, 12) . 234 (44%) of 530 patients had two or more adverse prognostic risk factors, including liver metastases (n=147 [28%]), haemoglobin lower than 10 g/dL (n=73 [14%]), ECOG performance status score greater than 0 (n=280 [53%]), and time since completion or discontinuation of previous therapy of less than 3 months (n=237 [45%]; table 1). Five patients allocated ramucirumab and two assigned placebo did not receive study treatment; therefore, the safety population comprised 523 patients, of whom 258 were allocated ramucirumab and 265 were assigned placebo.
Data cutoff for the current analysis was April 21, 2017. At data cutoff, 49 (19%) of 263 patients allocated ramucirumab and 36 (13%) of 267 assigned placebo continued to receive study treatment (figure 1). Median duration of follow-up in the full ITT population was 5·0 months (IQR 2·3-8·9). Median treatment duration was 12·1 weeks (IQR 6·0-21·0) with ramucirumab and 9·9 weeks (6·0-20·9) with placebo. The median number of cycles of docetaxel was four (IQR 2-6) in patients allocated ramucirumab and three (2-6) in those assigned placebo (appendix p 14). 93 (36%) of 258 patients allocated ramucirumab and 84 (32%) of 265 assigned placebo completed at least six cycles of docetaxel therapy; median relative dose intensities were 98·3% (IQR 90·9-100·1) and 98·8% (92·9-100·1), respectively. Patients who continued with ramucirumab or placebo mono therapy after the end of docetaxel treatment (64 vs 60) received a median of three (IQR 2-7) additional cycles of ramucirumab and two (1-5) of placebo.
At data cutoff, 341 progression-free survival events had occurred in the first 437 patients of the ITT population, 158 (73%) of 216 allocated ramucirumab and 183 (83%) of 221 assigned placebo (appendix p 15). Median progression-free survival was 4·07 months (95% CI 2·96-4·47) in patients allocated ramucirumab
Number at risk (number censored)
Ramucirumab plus docetaxel Placebo plus docetaxel 216 (0) 221 (0) 132 (21) 124 (16) 96 (6) 77 (1) 40 (16) 34 (6) 28 (2) 19 (3) 19 (3) 7 (8) 12 (2) 3 (1) 4 (6) 2 (1) 1 (2) 2 ( 221 (0) 117 (30) 102 (20) 87 (9) 67 (3) 34 (19) 28 (6) 21 (2) 14 (2) 10 (4) 4 (6) 7 (0) 3 (1) 2 (4) 2 (1) 0 ( and 2·76 months (2·60-2·96) in those assigned placebo (stratified HR 0·757, 95% CI 0·607-0·943; p=0·0118; figure 2A ). Estimated progression-free survival at 12 months was 11·9% (95% CI 7·1-18·0) in patients allocated ramucirumab and 4·5% (1·5-10·1) in those assigned placebo. A blinded independent central analysis was consistent with these results, with median progression-free survival of 4·04 months (95% CI 2·96-4·30) and 2·46 months (1·45-2·83), respectively (stratified HR 0·672, 95% CI 0·536-0·842; p=0·0005; figure 2B ). In prespecified subgroup analyses of progression-free survival, addition of ramucirumab to docetaxel improved progression-free survival across most subgroups ( figure 3 
Favours placebo Favours ramucirumab Figure 3 : Progression-free survival subgroup analyses in the first 437 randomised patients (intention-to-treat population) ECOG=Eastern Cooperative Oncology Group. HR=hazard ratio. *One patient allocated ramucirumab received nivolumab or placebo in a previous clinical trial, but we do not know whether that patient actually received nivolumab, so they are not included in this total for subgroup analysis.
53 (24·5%, 95% CI 18·8-30·3) of 216 patients allocated ramucirumab and 31 (14·0%, 9·4-18·6) of 221 assigned placebo (appendix p 15). These included nine (4%) complete responses in patients allocated ramucirumab and three (1%) in those assigned placebo. Objective responses by blinded independent central analysis were achieved by 48 (22·2%, 95% CI 16·7-27·8) of 216 patients allocated ramucirumab and 28 (12·7%, 8·3-17·1) of 221 assigned placebo. Because of the gatekeeping trial design, objective response superiority will be formally tested if the overall survival superiority test is positive. Median duration of response was 5·65 months (95% CI 3·9-7·1) for patients allocated ramucirumab and 4·17 months (2·9-5·5) for those assigned placebo. Of patients who received a previous immune-checkpoint inhibitor, five (36%) of 14 allocated ramucirumab and two (11%) of 19 assigned placebo achieved an objective response to treatment. Disease control occurred in 137 (63·4%, 95% CI 57·0-69·8) of 216 patients allocated ramucirumab and 124 (56·1%, 49·6-62·7) of 221 assigned placebo. Most patients allocated ramucirumab (107 [64%] of 168) had a reduction in tumour burden (figure 4). Reductions in tumour burden were seen less frequently in patients allocated placebo (86 [47%] of 183). At data cutoff, overall survival results were not mature, with 219 events.
Compliance for completion of the questionnaires for patient-reported outcomes in the full ITT population was 97% in both treatment groups at baseline and was 85% or higher at all on-therapy post-baseline visits. Mean scores for global quality of life and the EQ-5D-5L index were similar between treatment groups at baseline After administration of ramucirumab 10 mg/kg every 3 weeks in combination with docetaxel to patients with urothelial carcinoma, the geometric mean trough concentrations before doses two, three, and five were 15 µg/mL, 23 µg/mL, and 34 µg/mL, respectively. These data are consistent with those from previous studies in which ramucirumab was administered to patients with various types of cancer using this regimen. [30] [31] [32] Of 258 patients allocated ramucirumab who received treatment, 185 had serum samples analysed for the presence of anti-ramucirumab antibodies; 19 (10%) had positive samples at baseline and three (2%) had treatment-emergent anti-ramucirumab antibodies.
The most frequently reported treatment-emergent adverse events, regardless of causality, in either treatment group (any grade) were fatigue, alopecia, diarrhoea, decreased appetite, and nausea (table 2) . These events occurred predominantly at grade 1-2 severity. 156 (60%) of 258 patients allocated ramucirumab and 163 (62%) of 265 assigned placebo reported an adverse event of grade 3 or worse. No adverse event of grade 3 or worse was recorded that showed a difference in frequency of 5% or more in patients allocated ramucirumab compared with placebo. Grade 3 or worse anaemia was less common in patients allocated ramucirumab than in those assigned placebo (seven [3%] vs 28 [11%]), but the frequency of grade 3 or worse neutropenia was similar in both treatment groups (39 Adverse events leading to at least one dose adjustment (reduction, delay, or omission of any study drug) were reported in 88 (34%) of 258 patients allocated ramucirumab and 82 (31%) of 265 assigned placebo. The most common adverse event leading to dose adjustments for ramucirumab compared with placebo was febrile neutro penia (11 [4%] vs ten [4%]). Adverse events leading to discontinuation of any study treatment occurred in 39 (15%) of 258 patients allocated ramucirumab and 19 (7%) of 265 assigned placebo; sepsis was the most common adverse event leading to discontinuation of any treatment (five [2%] vs none [0%]).
Serious adverse events were reported for 100 (39%) of 258 patients allocated ramucirumab and 104 (39%) of 265 assigned placebo; these events were deemed by the investigator to be related to study treatment in 63 (24%) and 54 (20%) patients, respectively. Including events related by the investigator to disease progression, adverse events with an outcome of death on treatment or within 30 days of discontinuation were reported for 38 (15%) of 258 patients allocated ramucirumab and 43 (16%) of 265 assigned placebo; these events were deemed by the investigator to be related to study treatment in eight (3%) and five (2%) patients, respectively. Sepsis was the most common adverse event leading to death on treatment (appendix p 16), occurring in four (2%) patients allocated ramucirumab and no patients assigned placebo. One fatal event of neutropenic sepsis was reported in a patient allocated ramucirumab.
Discussion
Findings of the RANGE trial show that addition of ramucirumab to docetaxel is associated with a significant improvement in progression-free survival in patients with platinum-refractory advanced urothelial carcinoma. In this advanced patient population, progression-free survival outcomes were consistent across almost all major subgroups examined and confirmed by blinded central review. 44% of patients in this trial had two or more adverse prognostic risk factors at baseline, including the presence of liver metastases. 28, 29 A consistent progression-free survival benefit was seen for patients treated with ramucirumab plus docetaxel, irrespective of the number of associated risk factors, showing broad applicability of this regimen. The median progression-free survival of 2·76 months that was recorded with placebo plus docetaxel is consistent with historical data in the second-line setting, such that the noted improvement with ramucirumab plus docetaxel (4·07 months) was not attributable to underperformance of the control. 5, 13 Data for overall survival are immature at this time, precluding formal statistical analysis of objective response in accordance with the order of analyses specified in the statistical analysis plan. However, a higher proportion of patients allocated ramucirumab achieved an objective response compared with placebo (24·5% vs 14·0%), including nine complete responses with ramucirumab versus three with placebo, with non-overlapping 95% CIs. The objective response was consistent with findings of a phase 2 study of this treatment regimen and it was higher when compared indirectly with historical chemotherapy studies. 5, 13, 23 The objective response recorded in patients allocated ramucirumab in our study is also in line with that seen with immune-checkpoint inhibitors in other studies, although duration of response is longer with immune-checkpoint inhibitors. 6 Disease control was achieved by 63% of patients allocated ramucirumab in our study, which compares favourably with single-agent chemo therapy or immune-checkpoint inhibitors in other studies, underlining the active nature of this regimen in biomarker-unselected patients. 6, 13, 33 The combination of ramucirumab and docetaxel revealed no unexpected safety findings. The most common toxic effects were of grade 1-2 severity and manageable with supportive care alone or with dose reductions, as shown by the high median relative dose-intensity for all study drugs. Overall, addition of ramucirumab to docetaxel was not associated with an increase in occurrence of grade 3 or worse toxic effects typically associated with docetaxel in this patient population. Consistent with phase 2 data, 13 the most common haematological toxic effect in our study was neutropenia, reported at a similar frequency in both treatment groups; anaemia was less common in patients allocated ramucirumab. The frequency of toxic effects identified as potential class effects of antiangiogenic therapies-eg, grade 1-2 hypertension and bleeding-occurred at a higher frequency with ramucirumab than with placebo. Yet, the analyses of patient-reported out comes indicated no negative effect on quality of life. This finding is especially important for these patients, because most have a short life expectancy. Previous meta-analyses of second-line chemotherapy for patients with metastatic urothelial carcinoma showed that improvements in progression-free survival predict improvements in overall survival. 34 Based on this observation, and the improvement in objective response noted with ramucirumab and docetaxel, we believe our results are clinically significant.
Although our findings are positive, the study and the data available at the time of publication have limitations. Patients were not stratified according to all second-line Bellmunt risk factors and, as such, some imbalances were noted between treatment groups. A higher proportion of patients allocated ramucirumab had liver metastases (30% vs 26%) and a total Bellmunt risk score of 3 (18% vs 12%) compared with those assigned placebo, which might have affected study outcomes. The trial design allowed for inclusion of patients after treat ment with an immunecheckpoint inhibitor. How ever, only two such agentsatezolizumab (May, 2016) and nivolumab (February, 2017)-received regulatory approval for urothelial carcinoma before the end of the enrolment period of this study, and this approval was restricted to the USA. As a result, enrolment of such patients was limited. Further clinical experience with this cohort and with others in future studies will be needed to fully understand the efficacy of ramucirumab and docetaxel when used after treatment with a platinum-based regimen and immune-checkpoint inhibitors. Overall, median follow-up in the ITT population was fairly short (5 months) at this primary progression-free survival analysis, which can be attributed to the study population being a subset of the full ITT population and the overall rapid disease course leading to a short time to progression in patients with urothelial carcinoma. Survival data are pending maturity and will be informative once available.
Acknowledging the limitations and taken into context, the combination of ramucirumab and docetaxel shows significant activity without clear deleterious effects on quality of life, in a clinical setting of high unmet medical need. A high frequency of disease control will be attractive for patients for whom alternative chemo therapy options are limited and largely ineffective. Data for immunecheckpoint inhibitors have also become available in this setting, resulting in their widespread use in the USA. Inconsistencies have been seen with these agents, although long-term durable remission occurs in a subset of patients, and a survival advantage has been shown for pembrolizumab. 6 Our trial included 43 patients who had previously received immune-checkpoint inhibitors (appendix p 13). Two additional patients had been in clinical trials before RANGE in which they were randomly allocated either an immune-checkpoint inhibitor or placebo. Unfortunately, these numbers are small and only 33 of the 43 patients were included in the primary analysis of progression-free survival. However, responses were seen with ramucirumab and docetaxel in this population (five [36%] of 14 patients), suggesting activity. Further studies in this setting are needed. Based on the reported efficacy and tolerability, ramucirumab plus docetaxel is also an alternative treatment regimen in the setting after immune-checkpoint treatment or in patients ineligible for treatment with an immune-checkpoint inhibitor.
Future studies might also be of interest to investigate potential benefits of combining immune-checkpoint inhibitors and antiangiogenic agents. Findings of phase 2 and phase 3 studies have shown that about 20% of patients with platinum-refractory urothelial carcinoma achieve an objective response to immune-checkpoint inhibition. [6] [7] [8] Strategies to increase objective responses include combi nations of PD-1 or PD-L1 inhibitors with other immune-checkpoint inhibitors, chemotherapy, or antiangiogenic agents. 5, [35] [36] [37] [38] Ramucirumab in combination with PD-1 or PD-L1 inhibitors has shown promising clinical activity in multiple tumour types, including urothelial carcinoma, in the phase 1 setting, with no unexpected toxic effects. 36, 38, 39 More work is needed to understand combinatorial and sequencing approaches of these new classes of treatment for urothelial carcinoma.
In conclusion, the findings of the RANGE trial are consistent with results from a previous phase 2 study in which ramucirumab combined with docetaxel improved progression-free survival in patients with platinumrefractory advanced or metastatic urothelial carcinoma. 13 Up to now, ramucirumab is the only antiangiogenic agent with proven clinical activity in this patient population and, to our knowledge, RANGE represents the first phase 3 study to show a progression-free survival advantage over chemotherapy alone. No additive or unexpected toxic effects were seen when ramucirumab was combined with docetaxel. Together, these phase 2 and phase 3 data suggest a favourable benefit-to-risk ratio for this combination treatment and might represent a new regimen for this patient population.
